Get the Stockscreener App
28.28
1.65%
0.46
After Hours:
28.27
-0.01
-0.04%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $28.28, with a volume of 22.60M.
It is up +1.65% in the last 24 hours and up +1.80% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.82
Open:
$27.61
24h Volume:
22.60M
Relative Volume:
0.64
Market Cap:
$161.19B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
21.68
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
+1.73%
1M Performance:
+1.80%
6M Performance:
+3.89%
1Y Performance:
+12.04%
1-Day Range:
$27.59
$28.29
1-Week Range:
$27.12
$28.29
52-Week Range:
$23.62
$29.21
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.28 | 158.45B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,179.27 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 622.84B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 481.40B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer stock after-hours at EUR 25.04: minus 0.67 percent - AD HOC NEWS
Pfizer Says Eczema Drug Shows Significant Skin Clearance - Benzinga
Form 4 Pfizer For: 1 October By Investing.com - Investing.com Canada
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims - WTVB
Florida files lawsuit against Pfizer over COVID-19 vaccineReuters - Українські Національні Новини (УНН)
Does Pfizer (PFE) Have A New Growth Driver In Tilrekimig? - Simply Wall Street
Florida sues Pfizer and CEO Albert Bourla over COVID vaccine claims - Investing.com India
Pfizer Scores Promising Win for Experimental Eczema Drug - Yahoo Finance
Pfizer Sued By Florida AG Over its Covid-19 Vaccine Marketing - Bloomberg Law News
Florida AG sues Pfizer over 'misconduct' related to COVID vaccine risks - Seeking Alpha
Pfizer Sued by Florida Attorney General Over COVID-19 Vaccine Marketing - marketscreener.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results - grafa.com
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE) - Seeking Alpha
Pfizer presents tilrekimig data while Pfizer stock stays near its prior close - AD HOC NEWS
Pfizer reports positive phase 2 results for atopic dermatitis drug By Investing.com - Investing.com Canada
Pfizer Inc details 61% EASI‑75 response in tilrekimig trial - Mugglehead Investment Magazine
Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials - insights.citeline.com
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study - Business Wire
Are You Overpaying For Pfizer Stock Versus Its Rivals? - Trefis
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects? - Yahoo Finance
Pfizer and Moderna Lose Bids to Escape Bayer mRNA Patent Lawsuits - Lawyer Monthly
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE) - Seeking Alpha
Bayer's COVID Vax IP Suits Against Moderna, Pfizer Survive - Law360
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE) - Seeking Alpha
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit - reuters.com
Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says - marketscreener.com
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Yahoo Finance
Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? - Yahoo Finance
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? - Yahoo Finance
Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing - Yahoo Finance
Pfizer Inc. - Britannica
How AI Is Helping Match Patients to Clinical Trials Faster - Pfizer
Pfizer Inc Lobbyists, 2013 - OpenSecrets
Pfizer (NYSE:PFE) Back In Focus As Pricing Deal, Migraine Study, And Vaccine Milestone Shape Its Reset - Kalkine Media
Pfizer (PFE) Bets Big on RSV and Cancer Care - TipRanks
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash? - Insider Monkey
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? - Yahoo Finance
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study - TipRanks
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Pfizer stock reports a Q2 earnings beat at USD 28.43 - AD HOC NEWS
Pfizer stock heads into the open after a 0.82 percent gain - AD HOC NEWS
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth? - Yahoo Finance
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):